Thomas I. Barron

The start of any journey is one filled with hope, uncertainty and excitement. In January 2024, I embarked on my own personal commitment to start a business. As part of my commitment to that process, I also committed to learning as much as possible during. In order to hold myself accountable and share as much as possible with you, I’ve started The Entrepreneur’s Journal — a monthly report and reflection on my experiences the previous four weeks.

Abstract Background: Recent meta-analyses suggest that pre-diagnostic statin use is associated with reduced breast cancer-specific mortality. Studies have shown that high breast tumour expression of the statin target (3-hydroxy-3-methylglutaryl coenzyme-A reductase) is associated with lymph-node negative cancer. Therefore, we examined the association between pre-diagnostic statin use and; lymph node status, breast cancer-specific and all-cause mortality.

The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses.